Literature DB >> 10595828

Independent expression of serological markers of thyroid autoimmunity and hepatitis virus C infection in the general population: results of a community-based study in north-western Sardinia.

A Loviselli1, A Oppo, F Velluzzi, F Atzeni, G L Mastinu, P Farci, G Orgiana, A Balestrieri, P L Cocco, S Mariotti.   

Abstract

To assess the relationship between serological markers of thyroid autoimmunity and chronic hepatitis C, we surveyed the general population of two villages in the region of Sardinia, Italy, where infection with hepatitis viruses is endemic and the prevalence of autoimmune diseases is elevated. A total of 1310 subjects aged 6-88 years (65% of the total resident population) participated in the survey, and 1233 (94%; 444 males and 789 females) agreed to provide a blood sample. Autoantibodies to thyroid peroxidase (anti-TPO) were measured by radioimmunoassay; antibodies to HCV (anti-HCV) by a third generation enzyme immunoassay and borderline positive results confirmed by recombinant immunoblot assay. For both anti-HCV and anti-TPO the age- and gender-standardized prevalence rates (SPR) were calculated and the significance of the association between the two antibodies tested by Yates corrected chi2 test. The overall SPR for anti-HCV was 50.7x10(-3) (86/1,233), similar between men [49.1x10(-3) (22/444)] and women [52.3x10(-3) (64/789)]. The overall SPR for anti-TPO was 136.9x10(-3) (204/1,233), and that among women [201x10(-3) (174/789)] was almost 3-fold that among men [71.6x10(-3) (30/444)]. A concurrent anti-HCV and anti-TPO positivity was found in a small minority of subjects [8/1,233 (0.65%)], all women aged 57-81 years. The SPR for the two concurrent events was 3.3x10(-3), which was not significantly different (Yates corrected chi2 test = 0.65) from that expected under the assumption of unrelated events. To explore whether HCV infection is a risk factor for anti-TPO positivity, we designed a case-control study with anti-TPO positive subjects as the cases, and anti-TPO negative subjects as the controls. The age- and gender-adjusted odd ratio (OR) was 0.4 (95% CI 0.2,0.7), indicating a negative association. In conclusion, no evidence for epidemiological association of circulating thyroid autoantibodies and antibodies to HCV was found. Our findings do not therefore support a pathogenetic link between HCV infection and thyroid autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595828     DOI: 10.1007/BF03343626

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  39 in total

1.  Anti-thyroid autoantibodies and hepatitis C virus.

Authors:  N Colas-Linhart; B Bok; P Marcellin; M Pouteau; J P Benhamou
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

Review 2.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

3.  Latent autoimmune thyroid disease in patients with chronic HCV hepatitis.

Authors:  D Pateron; D J Hartmann; J C Duclos-Vallée; H Jouanolle; M Beaugrand
Journal:  J Hepatol       Date:  1993-03       Impact factor: 25.083

Review 4.  Italian serum exchange workshop for the standardization of organ specific autoantibodies. ImmunoEndocrinology Study Group of the Italian Society of Endocrinology.

Authors:  U Di Mario; C Betterle; F Dondero; G F Fenzi; S Mariotti; F Trimarchi
Journal:  J Endocrinol Invest       Date:  1994-05       Impact factor: 4.256

5.  Thyroid abnormalities in patients with chronic viral hepatitis.

Authors:  M J Huang; S S Wu; Y F Liaw
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

6.  High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy.

Authors:  A Tran; J F Quaranta; S Benzaken; V Thiers; H T Chau; P Hastier; D Regnier; G Dreyfus; C Pradier; J L Sadoul
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

7.  Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C.

Authors:  E Baudin; P Marcellin; M Pouteau; N Colas-Linhart; J P Le Floch; C Lemmonier; J P Benhamou; B Bok
Journal:  Clin Endocrinol (Oxf)       Date:  1993-12       Impact factor: 3.478

8.  Thyroid hypofunction related with the progression of human immunodeficiency virus infection.

Authors:  A Olivieri; M Sorcini; P Battisti; C Fazzini; E Gilardi; Y Sun; E Medda; M Grandolfo; G Tossini; S Natili
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

Review 9.  Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature.

Authors:  Y Nagayama; K Ohta; M Tsuruta; A Takeshita; H Kimura; K Hamasaki; K Ashizawa; K Nakata; N Yokoyama; S Nagataki
Journal:  Endocr J       Date:  1994-10       Impact factor: 2.349

10.  Prevalence of thyroid autoantibodies is not increased in blood donors with hepatitis C virus infection.

Authors:  J Boadas; J Rodríguez-Espinosa; J Enríquez; F Miralles; F J Martínez-Cerezo; P González; P Madoz; F Vilardell
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

View more
  20 in total

1.  Risk of malignant lymphoma following viral hepatitis infection.

Authors:  Pierluigi Cocco; Giovanna Piras; Maria Monne; Antonella Uras; Attilio Gabbas; Maria G Ennas; Angelo Palmas; Marco Murineddu; Stefania Collu; Massimo Melis; Marco Rais; Pierfelice Todde; Maria G Cabras; Emanuele Angelucci; Giovannino Massarelli; Alexandra Nieters
Journal:  Int J Hematol       Date:  2008-05-01       Impact factor: 2.490

Review 2.  Hepatitis C and interferon induced thyroiditis.

Authors:  Yaron Tomer
Journal:  J Autoimmun       Date:  2010-05       Impact factor: 7.094

3.  Prevalence of silent celiac disease in patients with autoimmune thyroiditis from Northern Sardinia.

Authors:  G F Meloni; P A Tomasi; A Bertoncelli; G Fanciulli; G Delitala; T Meloni
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

4.  High prevalence of papillary thyroid carcinoma in nodular Hashimoto's thyroiditis at the first diagnosis and during the follow-up.

Authors:  F Boi; F Pani; P G Calò; M L Lai; S Mariotti
Journal:  J Endocrinol Invest       Date:  2017-09-05       Impact factor: 4.256

5.  Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules.

Authors:  F Boi; L Minerba; M L Lai; B Marziani; B Figus; F Spanu; A Borghero; S Mariotti
Journal:  J Endocrinol Invest       Date:  2012-08-29       Impact factor: 4.256

6.  Is there anything to the reported association between Helicobacter pylori infection and autoimmune thyroiditis?

Authors:  Paolo A Tomasi; Maria P Dore; Giuseppe Fanciulli; Franca Sanciu; Giuseppe Realdi; Giuseppe Delitala
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 7.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 8.  Interferon induced thyroiditis.

Authors:  Yaron Tomer; Francesca Menconi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

9.  Fifteen-year follow-up of thyroid function in lithium patients.

Authors:  A Bocchetta; F Cocco; F Velluzzi; M Del Zompo; S Mariotti; A Loviselli
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

10.  Expression of endocrine autoantibodies in chronic hepatitis C, before and after interferon-alpha therapy.

Authors:  G Murdolo; D Francisci; F Forini; F Baldelli; G Angeletti; G Stagni; F Santeusanio; F Calcinaro; A Falorni
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.